OSE Immunotherapeutics Reports Promising Phase 2 Trial Outcomes for Lusvertikimab in Ulcerative Colitis Treatment.

Olutasidenib received FDA approval on December 1, 2022. This drug belongs to the class of miscellaneous antineoplastics.

IASO Biotechnology announced that the FDA has approved its application for a new drug, Equecabtagene Autoleucel (Eque-cel), a fully human anti-BCMA CAR T cell therapy.

Rebyota, a fecal microbiota product, is used to prevent the recurrence of Clostridioides difficile infection (CDI).

Enterprise Therapeutics has today revealed that the first participant with cystic fibrosis has been administered a dose in its Phase 2a study of ETD001.

Etranacogene dezaparvovec, marketed under the brand name Hemgenix, is a gene therapy used to treat adults with Hemophilia B.

Merck Reveals Preliminary Findings from Phase 2b/3 Study of Clesrovimab (MK-1654), an Experimental Monoclonal Antibody for RSV Prevention in Infants.

Teplizumab, marketed under the brand name Tzield, was approved by the FDA on November 17, 2022.

FDA Greenlights Samsung Bioepis' EPYSQLI® (eculizumab-aagh) as a Biosimilar to Soliris (eculizumab).

Mirvetuximab soravtansine, marketed under the brand name Elahere, is approved by the FDA for the treatment of adults with ovarian cancer.

Zymeworks Receives FDA Approval for ZW191 Investigational New Drug Application, a Cutting-Edge Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate.

Tremelimumab (brand name: Imjudo) is indeed FDA-approved. It is a monoclonal antibody that belongs to the class of drugs known as anti-CTLA-4 monoclonal antibodies.